Not applicableUnknownNCT04168281What this trial is testingWatchful Observation of Patients With LD-SCLC Instead of the PCIWho this might be right forSmall-cell Lung Cancer Sergiusz Nawrocki 80
Not applicableLooking for participantsNCT05985330What this trial is testingPilot Study of the Contribution of Fractional Exhaled Nitric Oxide as a Prognostic Marker of Response to Anti-PD-L1 Immunotherapy in Non-small Cell Lung CancerWho this might be right forMetastatic Non-small Cell Lung Cancer Centre Hospitalier Universitaire Dijon 56
Early research (Phase 1)Study completedNCT04423029What this trial is testingDF6002 Alone and in Combination With NivolumabWho this might be right forSolid Tumors Dragonfly Therapeutics 170
Not applicableLooking for participantsNCT06109454What this trial is testingObservation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Cancer After Radical SurgeryWho this might be right forNon-small Cell Lung Cancer Liaoning Cancer Hospital & Institute 240
Testing effectiveness (Phase 2)Study completedNCT02178722What this trial is testingStudy to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected CancersWho this might be right forMicrosatellite-instability (MSI) High Colorectal Cancer (CRC)Endometrial CancerHead and Neck Cancer+11 more Incyte Corporation 444
Not applicableUnknownNCT01344005What this trial is testingStandard Medical Care or Urgent Chest X-ray in Diagnosing Lung Cancer in Smokers With Chest Symptoms Who Are Older Than 60 YearsWho this might be right forLung CancerTobacco Use Disorder Wales Cancer Trials Unit 386
Early research (Phase 1)Study completedNCT00569712What this trial is testingStudying Genes in Blood and Lung Fluid Samples From Patients With Chronic Obstructive Pulmonary Disease With or Without a Previous Diagnosis of Lung Cancer or With Asthma Treated With Budesonide and FormoterolWho this might be right forLung CancerPrecancerous Condition British Columbia Cancer Agency 30
Testing effectiveness (Phase 2)Study completedNCT02576431What this trial is testingTest the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsWho this might be right forSolid Tumors Harboring NTRK Fusion Bayer 215
Large-scale testing (Phase 3)Active Not RecruitingNCT05502237What this trial is testingZimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung CancerWho this might be right forNon-small Cell Lung Cancer Gilead Sciences 1,021
Not applicableEnded earlyNCT03488472What this trial is testingRadiosurgery Plus NovoTTF-200A for Metastatic Small Cell Lung Cancer to the BrainWho this might be right forBrain MetastasesSmall Cell Lung Cancer Drexell Hunter Boggs 1
Testing effectiveness (Phase 2)Study completedNCT00137839What this trial is testingErlotinib in Women With Previously Untreated Adenocarcinoma of the LungWho this might be right forAdenocarcinomaNon-small Cell Lung Cancer Pasi A. Janne, MD, PhD 84
Testing effectiveness (Phase 2)Study completedNCT02797964What this trial is testingA Phase 1/2 Trial of SRA737 in Subjects With Advanced CancerWho this might be right forAdvanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL) Sierra Oncology LLC - a GSK company 107
Not applicableLooking for participantsNCT07696832What this trial is testingEfficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort StudyWho this might be right forPatients Must Have Histologically or Cytologically Confirmed Locally Advanced or Metastatic NSCLCEGFR Mutation-negative and ALK Rearrangement-negativeEastern Cooperative Oncology Group Performance Status (ECOG PS) Score of 0 to 2+2 more Guangdong Association of Clinical Trials
Early research (Phase 1)Ended earlyNCT04348292What this trial is testingSirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung CancerWho this might be right forLung Non-Small Cell CarcinomaStage I Lung Cancer AJCC v8Stage IA1 Lung Cancer AJCC v8+7 more Emory University 3
Early research (Phase 1)Study completedNCT04006301What this trial is testingFirst-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C MutationWho this might be right forNeoplasmsAdvanced Solid TumorsNon-small Cell Lung Cancer+1 more Janssen Research & Development, LLC 10
Testing effectiveness (Phase 2)Ended earlyNCT05397171What this trial is testingA First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid TumoursWho this might be right forUrinary Bladder NeoplasmsColorectal CancerCarcinoma, Non-Small-Cell Lung AstraZeneca 17
Testing effectiveness (Phase 2)UnknownNCT04872634What this trial is testingEvaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor TreatmentWho this might be right forNon-small Cell Lung Cancer NKMAX Co., Ltd. 24
Not applicableStudy completedNCT03727477What this trial is testingEfficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving LorlatinibWho this might be right forNon-small Cell Lung Cancer MetastaticALK Gene Rearrangement PositiveROS-1 Gene Rearrangement Positive Intergroupe Francophone de Cancerologie Thoracique 291
Testing effectiveness (Phase 2)UnknownNCT04180501What this trial is testingSRS Sequential Sindilimab in Brain Metastasis of NSLSCWho this might be right forNSCLC Stage IVBrain MetastasesSRS+1 more Xiaorong Dong 25
Large-scale testing (Phase 3)Looking for participantsNCT06956001What this trial is testingFirmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q MutationWho this might be right forEGFRNSCLC (Advanced Non-small Cell Lung Cancer) Allist Pharmaceuticals, Inc. 300